Arkolith/Insider Trading/PHAS/Form 4

Sharp John P

Chief Financial OfficerPhaseBio Pharmaceuticals Inc (PHAS) · full profile →Form 4 · filed Nov 3, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 3, 2021Option exercise(M)8K$1.68$13K58K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 3, 2021Option exercise(M)8K$1.68$13K91K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001169245-21-000103) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML